← Leaderboards
Nishant Gupta
University Of Cincinnati
$1,472,015
Attributed
$1,472,015
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $283K · FY2017–25$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,472,015 · 4
By mechanism
R21$719,572 · 2
R34$712,443 · 1
R13$40,000 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Cincinnati
Same institution · by research overlap
- Francis X McCormack$13,631,889
- Joel Tsevat$14,266,195
- Manoocher Soleimani$3,136,920
- Timmy C Lee$4,863,769
- Andrew M Naidech$10,150,469
Others in their field
Other Emerging Leaders on “Lung Diseases”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$49,374,001
- Prasant Mohapatra · University Of California At Davis$40,346,250
- Lynn Briscoe · Leidos Biomedical Research, Inc.$23,229,499
- Ashlin Bolton · Broad Institute, Inc.$22,970,454
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$17,335,818
Research focus
Lung DiseasesLymphangioleiomyomatosisDesignFrap1 GenePathway InteractionsFemaleQuality Of LifeMutationSirolimusSafetyPulmonary Function Test/Forced Expiratory Volume 1InternationalTuberous SclerosisGenesWomanRespiratory FailureNovel TherapeuticsPulmonary Function DeclineFutureSymptomsPatient Outcomes AssessmentsPrognosticBaseLung
Grant awards (8)
Patient centered outcome measures and prediction tools in lymphangioleiomyomatosis$123,917
R21 · FY2025 · HL · contact PI
Patient centered outcome measures and prediction tools in lymphangioleiomyomatosis$150,155
R21 · FY2024 · HL · contact PI
Menstrual Cycle-Related Symptom Variability as a Prognostic Indicator in Lymphangioleiomyomatosis$202,500
R21 · FY2023 · TR · contact PI
Menstrual Cycle-Related Symptom Variability as a Prognostic Indicator in Lymphangioleiomyomatosis$243,000
R21 · FY2022 · TR · contact PI
2022 International Lymphangioleiomyomatosis (LAM) Research Conference$40,000
R13 · FY2022 · HL · contact PI
Resveratrol and Sirolimus in LAM Trial (RESULT)$233,098
R34 · FY2019 · HL · contact PI
Resveratrol and Sirolimus in LAM Trial (RESULT)$229,320
R34 · FY2018 · HL · contact PI
Resveratrol and Sirolimus in LAM Trial (RESULT)$250,025
R34 · FY2017 · HL · contact PI